Our Members

Member organisations

Our member organisations provide direct services in each state and territory around Australia. The range of services may differ from one organisation to another but all are community-based, not for profit organisations. Each organisation is listed below.

Hepatitis ACT

1300 301 383
[email protected]
www.hepatitisact.com.au

Hepatitis New South Wales

02 9332 1853
[email protected]
www.hep.org.au

Hepatitis Queensland

07 3846 0020
[email protected]
www.hepqld.asn.au

Hepatitis SA

08 8362 8443
[email protected]
www.hepatitissa.asn.au

Hepatitis Victoria

03 9380 4644
[email protected]
www.hepvic.org.au

08 9227 9800
[email protected]
www.hepatitiswa.com.au

Northern Territory AIDS & Hepatitis Council

08 8944 7777
[email protected]
www.ntahc.org.au

Tasmanian Council on AIDS, Hepatitis & Related Diseases

03 6234 1242
[email protected]
www.redthread.org.au

Page updated 04 June 2019

Latest

Parliamentary Morning Tea: We can eliminate hepatitis C!

The Parliamentary Friends Group for Action of Blood Borne Viruses Co-Chairs, Tim Wilson, MP and Senator Louise Pratt invite you to a Parliamentary Morning Tea on Thursday 12 November.
Renewed calls for Needle & Syringe Programs in prisons ahead of International Drug Users Day

The Australian Injecting and Illicit Drug Users League (AIVL) and Hepatitis Australia are highlighting international calls for Needle and Syringe Programs (NSPs) in prisons, along with a greater focus on harm reduction initiatives, ahead of International Drug Users Day on 1 November.
Investment in hepatitis research needs to be accompanied by National Strategy implementation funding

6 October 2020 - Hepatitis Australia welcomes the Australian Government’s commitment to diverse hepatitis research, however we remain concerned that the 2019 Health Budget funding for hepatitis commitments is yet to hit the ground.
Investment in liver cancer medicines matched with prevention are changing Australian lives

6 October 2020 - Hepatitis Australia welcomes the Australian Government’s significant investment of $230 million to expand the listing of Tecentriq® and Avastin® (atezolizumab and bevacizumab) on the Pharmaceutical Benefits Scheme (PBS).